Advanced Filters
noise

Vaccines Clinical Trials

A listing of Vaccines medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 506 clinical trials

A Study to Learn About mRNA Vaccines Against Influenza in Adults

The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All …

18 years of age All Phase 2
C CorEvitas Clinical Research Associate

RSV Vaccine Pregnancy Registry

The research question is: What is the risk of adverse pregnancy outcomes, including preterm birth, hypertensive disorders, and other maternal and neonatal/infant outcomes, following exposure to RSV vaccine between 32 weeks, 0 days and 36 weeks, 6 days of gestation in the CorEvitas Respiratory Syncytial Virus Vaccine Pregnancy Registry (RSV-PR)? …

18 - 50 years of age Female Phase N/A
F Fei Jin

Clinical Trials of Quadrivalent Influenza Vaccine

This clinical trial adopts a seamless design of phase I/II, conducted in two stages: phase I and phase II. Phase I is the age/dose ramp up stage, and phase II is the dose expansion stage.The purpose of this clinical trial is to evaluate the safety and tolerability of different doses …

18 years of age All Phase 1/2

Genomics and COVID-19 Vaccine Adverse Events

Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide. Study hypothesis: there …

5 - 99 years of age All Phase N/A

Preparing for Maternal GBS Vaccine Trials in Africa

Infections are one of the key causes of newborn deaths. Among them, Group B Streptococcus (GBS) is the leading cause of sepsis and bacterial meningitis in the first 90 days of life. Fortunately, GBS vaccines for pregnant women, a powerful tool for fighting infections, are currently in development. Once vaccine …

years of age All Phase N/A

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

A cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.

2 years of age All Phase 4
C Chris Guure

Testing a Biometric Identification System to Improve Malaria Vaccine Completion

Receiving all four doses of the malaria vaccine can significantly protect children against malaria illness, hospitalization, and death. However, in Ghana, only 46% of children complete the full vaccination sequence. More broadly, many children in Ghana do not receive the full set of recommended pediatric vaccinations. To address this, Simprints, …

15 - 49 years of age Female Phase N/A

"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake

This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing HPV vaccination.

years of age All Phase N/A
A Andres Jimenez

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.

1 - 11 years of age All Phase 3
H Hui Zhang

Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine

This study is a randomized, blinded study to evaluate the lot-to-lot consistency of immunogenicity, safety, and immune persistence of three consecutive manufacturing lots of EV71 vaccine, in 1500 children aged 6-35 months. The primary immunogenicity endpoint is the anti-EV71 neutralizing antibody geometric mean titer (GMT) 30 days after the final …

6 - 35 years of age All Phase 4

Simplify language using AI